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En Bloc Approach
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Joachim Diebold, MD,Þ Ju¨rg Vosbeck, MD,Þ Bernhard Allgayer, MD,* Klaus Strobel, MD,*
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Objectives: The aim of this study was to assess the performance of dynamic
contrast-enhanced computed tomography of the prostate in patients with
biopsy-proven prostate cancer.
Material and Methods: A total of 46 male patients (median age, 65 years;
range, 49Y73 years) with biopsy-proven prostate cancer underwent an en bloc
computed tomography perfusion (CTP) scan of the prostate before surgery.
The perfusion parameters mean transit time (MTT), blood flow (BF), and
blood volume (BV), as well as the microvessel density (MVD) of surgical
specimens were determined. Differences in CTP parameters and MVD among
postsurgical Gleason score (sGS) and postsurgical combined Gleason grade
(sGG) groups were analyzed. Spearman correlation coefficients were deter-
mined between CTP parameters and presurgical biopsy-derived Gleason score
(bGS), presurgical biopsy-derived combined Gleason grade (bGG), sGS, sGG,
MVD, and pathological tumor stage. A linear regression analysis was carried out
for exogenous variables BF, BV, MTT, bGS, and presurgical biopsy-derived
combined Gleason grade and endogenous variables sGS, sGG, MVD, and T
stage. A receiver operating characteristics analysis was performed to analyze the
discriminating performance of CTP parameters and bGS between intermediate-
and high-grade tumors.
Results: The mean perfusion parameters within the prostate tissue were
as follows: BF, 39.1 T 13.4mL/100mLminj1; BV, 4.9 T 2.4mL/100mL; andMTT,
8.9 T 3.7 seconds. The mean MVD of the tumor tissue was 144.3 T 55.6/mm2.
Computed tomography perfusion parameters andMVDwere significantly higher
in patients with high-grade tumors compared with those with intermediate-grade
tumors (P G 0.01 for BF, BV, and MVD). Only BVand MVD were significantly
different among sGS and sGG groups. Moderate correlations were found be-
tween BF and sGS (0.38) and between BV and sGS (0.43). Linear relations of
BV to sGS and to sGG were found. Blood volume (area under the curve, 0.86)
was superior to bGS (area under the curve, 0.75) in discriminating high-grade
from intermediate-grade tumors.
Conclusion: Computed tomography perfusion parameters derived by en bloc
perfusion of the prostate are higher in high-grade tumors compared with
intermediate-grade tumors. Blood flow and BV correlate with the definitive
Gleason score. Blood volume predicts high-grade tumors better than does the
Gleason score of biopsy specimens. Further studies are needed to determine
a potential role for CTP in prostate cancer patients.
Key Words: perfusion imaging, computed tomography, prostate cancer,
Gleason score, oncology, multimodal imaging
(Invest Radiol 2014;49: 571Y578)
P rostate cancer is the most frequent noncutaneous malignancy inmen in developed countries, with an annual incidence of 0.062%.1
Its comparably low mortality is attributed to an overall early detection,
to varying tumor behaviors from almost benign to rare highly aggres-
sive subtypes, as well as to several effective therapeutic options.
If prostate cancer is suspected in a patient, the work-up usually
includes biopsies guided by transrectal ultrasound (TRUS) to confirm
the tumor and provide a tentative estimate of its aggressiveness, which
will have implications on further therapeutic decisions. It is, however,
well known that the presurgical and postsurgical histopathological re-
sults, that is, the Gleason grading, may differ considerably.2Y4
To noninvasively obtain further information about the tumor’s
aggressiveness before therapy, magnetic resonance imaging (MRI)
has gained widespread acceptance during the last decade. Functional
methods such as dynamic contrast-enhanced (DCE) MRI, diffusion-
weighted imaging, and magnetic resonance spectroscopy are used to
locate the tumor within the prostate and enable targeted biopsy.5Y14
It was recently shown that multiparametric MRI is precise in detect-
ing even low-risk prostate cancer, with the accuracy depending on
tumor volume and Gleason grade.9
Dynamic contrast-enhanced computed tomography (CT) has
demonstrated its ability for the noninvasive assessment of angiogene-
sis by determining functional parameters of tissue microcirculation in
different malignant lesions.15Y21 There are also potential roles for DCE
CT in prostate cancer, such as the initial tumor assessment, follow-up,
and monitoring of therapy response in patients with contraindications
to MRI, such as pacemakers or ferromagnetic vascular coils.9,22Y25 The
prostate, however, is comparably difficult to assess with CT-perfusion
(CTP) because of artifacts from neighboring pelvic bones and the
usually small volume of prostate cancer as well as coexisting benign
prostatic hyperplasia and chronic prostatitis. On the other hand,
several tumor spots of varying grades may coexist or even diffusely
infiltrate the prostate parenchyma rather than form circumscribed
compounds. The few available studies about CTP in prostate cancer
have partly contradictory results concerning both its feasibility and
its usefulness.22,23,26Y28 Korporaal and coworkers28 provided evi-
dence that the results of DCE CT are not substantially influenced by
the choice of the tracer kinetic model. One recent feasibility study
addressed the relationship of image noise and voxel size in DCE CT of
the prostate but provided no histopathological information.11 Another
recent study investigating histopathological correlation found a rela-
tionship between blood volume (BV) and microvessel density (MVD).
However, there are yet no data available about the association of per-
fusion parameters derived from DCE CT and clinically relevant histo-
pathological grading such as the Gleason score (GS).
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Thus, the aims of the present study were to assess the whole
prostate with DCE CT using an en bloc approach and to analyze the re-
lationship between perfusion parameters and histopathological grading.
MATERIAL AND METHODS
Patients
This prospective study was approved by the institutional re-
view board and by the cantonal ethics committee. All patients pro-
vided informed signed consent before the examinations.
To be included into the study, patients had to meet the following
criteria: biopsy-proven prostate cancer within the last 8 months, referral
for initial staging examination by abdominal CT and/or bone scan, will-
ingness to undergo an additional CT scan to acquire DCE image data
sets, and a scheduled start of therapy in less than 5 months. The ex-
clusion criteria were renal insufficiency (renal clearance G30 mL/min)
without dialysis, known allergy or hypersensitivity to iodinated contrast
medium, and untreated hyperthyroidism. Ninety-eight male patients
(median age, 67 years; range, 49Y84 years) were finally included and
underwent the CTP scan.
Thereof, 18 patients (18%) were excluded after the scan because
of technical reasons such as power injector malfunction (7 patients),
movement artifacts (4 patients), and beam hardening artifacts due to hip
prosthesis (5 patients) or metal markers within the prostate (2 patients).
Thirty-two patients (32%) were excluded afterward because they did
not undergo prostatectomy, making definitive histopathological Gleason
grading unavailable. Of these, 2 patients (3%) were treated palliatively
by transurethral resection of the prostate. Fourteen patients (14%) re-
ceived external beam radiation therapy, 4 patients (5%) underwent low-
dose brachytherapy with seeds, and 5 patients (6%) were treated with
palliative antiandrogen drugs. Awatchful waiting strategy was chosen in
4 patients (5%). Three patients (4%) refrained from therapy against
medical advice. Two patients (3%) were excluded because the time in-
terval between CT scan and prostatectomy was more than 150 days.
The remaining 46 patients were treated by curative surgery
(38 by robot-assisted laparoscopic radical prostatectomy and 8 by
open radical prostatectomy) and qualified for analysis. The median time
interval between biopsy and CT scan was 19 days (range, 0Y202 days).
The median time interval between the CTP scan and prostatectomy
was 63 days (range, 10Y147 days). Median time between biopsy and
prostatectomy was 83 days (range, 19Y244 days).
The presurgical (bGS) and postsurgical (sGS) GS, the pre-
surgical (bGG) and postsurgical (sGG) combined Gleason grade (GG),
and pathological tumor stage were available for all 46 patients. Suffi-
cient tissue material for MVD assessment was available for 32 patients.
The term combined Gleason grade (GG) was used to characterize the
2 Gleason patterns (eg, bGG 7 = 4 + 3), whereas the usual GS refers
to the sum of the 2 patterns (eg, bGS 7). It is known that, for example,
7 = 4 + 3 tumors may exhibit more aggressive characteristics than 7 = 3 +
4 tumors.29Y31 Low-grade tumors are defined as a GS of 6 or lower,
intermediate tumors correspond to a GS of 7, and high-grade tumors
entail a GS of 8 or higher. A detailed overview of patient data is given
in Table 1.
DCE-CT Scan
All CT scans were performed using a Somatom Definition
Flash scanner (Siemens Healthcare, Erlangen, Germany). Depending
on whether patients were referred for staging CT or bone scan, they
underwent a CTP that was integrated into the abdominal staging
CT scan using a split-injection protocol or a CTP scan only. The
covered scan length of the perfusion scan was 7 cm. The duration of
the CTP scan was 60 seconds, with a rotation time of 1 second, corre-
sponding to a sampling interval of 1 second. With such a rather lengthy
protocol, high reproducibility of perfusion parameters can be obtained.32
The tube current was set to 100 mAs, and the tube voltage, to 100 kVp
(fixed parameters). Scanning started with a delay of 10 seconds after
the injection of 40 mL of iodinated contrast medium (Ultravist 370;
Bayer Healthcare, Leverkusen, Germany), followed by a flush of 50 mL
of NaCl at 4.5 mL/s. The contrast agent was injected into an antecubital
vein using a dual-head pump injection device (Stellant D; Medrad,
Warrendale, PA). The slice collimation was 64  0.6. The CTP recon-
struction increment was 3 mm at 5-mm slice width. The image recon-
struction was performed with a 512  512Ypixel matrix.
Image Evaluation
All evaluations were performed by 2 experienced radiologists
in consensus. The perfusion parameters blood flow (BF), BV, and mean
transit time (MTT) were determined by postprocessing on a commer-
cially available computer workstation using a dedicated perfusion as-
sessment software (syngo VPCT Body; Siemens Healthcare). A data
set motion correction and a noise reduction algorithm were applied
automatically. The processing thresholds were set to 0 and 150 HU
to exclude bone and other hyperdense material. The window width
TABLE 1. Patient Data
Parameter n
No. patients 46
Age, median (range), y 65 (49Y73)
PSA, median (range), Kg/L 8.7 (2.6Y82.4)
bGS
6 9
7 30
8 5
9 2
bGG
6 (3 + 3) 9
7 (3 + 4) 20
7 (4 + 3) 10
8 (4 + 4) 4
8 (5 + 3) 1
9 (4 + 5) 1
9 (5 + 4) 1
sGS
6 1
7 36
8 6
9 3
sGG
6 (3 + 3) 1
7 (3 + 4) 20
7 (4 + 3) 16
8 (4 + 4) 5
8 (5 + 3) 1
9 (4 + 5) 3
9 (5 + 4) 0
Pathological tumor stage
pT2a 2
pT2b 0
pT2c 34
pT3a 6
pT3b 4
PSA indicates prostate-specific antigen; bGS, Gleason score of biopsy speci-
mens; bGG, combined Gleason grade of biopsy specimens; sGG, combined
Gleason grade of surgical specimens; sGS, Gleason score of surgical specimens.
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and center for reference vessel input were 300 and 150 HU, respec-
tively. The relative threshold for inside and outside was 50%. An
adaptive smoothing filter was applied. The vendor’s default algorithmic
parameters were applied.
For every patient, an individual arterial input fraction was
determined by placing an analytic region of interest into the external
iliac artery to obtain a time attenuation curve. This indirect method
was chosen because the internal iliac artery, which supplies the prostate,
was not depicted adequately within the scan range in all patients. It was
presumed that the time attenuation curves derived from both arteries
were similar.
Three-dimensional color-coded maps of BF, BV, and MTTwere
generated with a sequential 2-compartment model (modified Patlak
approach). Blood flow is defined as the amount of blood flowing
through 100 mL of prostate tissue within 1 minute. Mean transit time
is defined as the average time of contrast agent residence within
the prostate tissue. Blood volume is the product of BF and MTT and
is defined as the amount of blood within 100 mL of prostate tissue.
Blood volume can be expressed as proportion of the total volume of a
dedicated voxel.
The perfusion parameter values of the prostate were determined
using an en bloc approach. For this purpose, an analytic volume of in-
terest was placed on the prostate on the time-maximum intensity pro-
jection images, which was simultaneously transferred to the spatially
coregistered color-coded data sets by software automatism. The contour
of the volume of interest was adapted to the contour of the prostate on
all time-maximum intensity projection images, in all 3 planes.
Histopathological Analysis
The GS of biopsy specimens and prostatectomy specimens as
well as tumor stage of prostatectomy specimens were determined
according to internationally standardized methods in pathology.33,34
For the characterization of the tumor vasculature, the mean
intratumoral MVD was quantitatively assessed according to immuno-
histochemical cluster of differentiation molecule 34 (CD34) staining.
Formalin-fixed prostatectomy specimens embedded in paraffin could
be obtained from 32 patients. In the remaining 14 patients, the amount of
material that was left after standard histopathological examination was
too small to allow for MVD analysis. Specimens were cut into 4-Hm
slices and fixed to histology slides (x-tra; Leica Biosystems, Nussloch,
Germany). After hematoxylin/eosin staining, slides were stained with
CD34 antibody (1:30, NCL-L END, Novocastra; Leica Biosystems)
using an automated staining system (BenchMark XT; Ventana Medical
Systems, Oro Valley, AZ). The slides were then scanned with a slide
scanner (iScan Coreo; VentanaMedical Systems). One pathologist blinded
to clinical and imaging data performed the histopathological analysis by
visually counting the positive microvessels on the scanned images using
public domain software (imageJ, http://rsbweb.nih.gov/ijIm Cache).
Statistical Analysis
Differences in CTP parameters of the prostate and tumoral MVD
among groups of tumors with different grading were evaluated using
Mann-Whitney U test and/or Kruskal-Wallis test. Correlations be-
tween pairs of variables (CTP parameters, MVD, bGS, bGG, sGS,
sGG, T stage) were assessed using Spearman rank correlation coef-
ficient. Results were interpreted as strong correlation if between T0.5
and T1.0, moderate correlation between T0.3 and T0.49, and weak
correlation between T0.1 and T0.29, thereunder no correlation.35 A
linear regression analysis was performed to assess the relationship of
exogenous variables BF, BV, MTT, bGS, and bGG and endogenous
variables sGS, sGG, MVD, and T stage. A receiver operating charac-
teristics (ROC) analysis was carried out to analyze the discriminating
performance of CTP parameters and bGS between intermediate- and
high-grade tumors. A P value of G0.05 was considered statistically
significant. All analyses were performed using the software IBM SPSS
Statistics 19.0.1 (SPSS Inc, Chicago, IL).
RESULTS
Histopathology
In both biopsy and prostatectomy specimens, the most common
GS was 7 (range, 6Y9) and the most common GG was 7 (3 + 4). His-
topathological upgrading from biopsy to prostatectomy specimens oc-
curred in 12 patients, and downgrading, in 4 patients. A change in the
GG occurred in 26 patients (56%; range, j1 to +4 grades). Whereas
there were initially 9 patients diagnosed with bGS 6, there was only
1 patient left with sGS 6. The most common first Gleason pattern in
biopsy samples was 3, whereas the most common first pattern was 4
in surgical samples. According to the final histopathological results,
there was 1 low-grade tumor (2%, sGS 6), 36 intermediate-grade tu-
mors (78%, sGS 7), and 9 high-grade tumors (20%, sGS 8 and 9).
The most common tumor stage was pT2c (34 patients, 74%),
denoting invasion of both lobes of the prostate. Extracapsular spread
(T3) occurred in 10 patients (22%), thereof invasion of the seminal
vesicles (T3b) in 4 patients (9%). The mean MVD was 144.3 T 55.6
microvessels/mm2.
An overview of relevant data is given in Table 1.
DCE-CT and Statistical Analyses
The calculated mean effective individual radiation dose was
25.6mSv. The BF in prostate tissuewas 39.1 T 13.4 mL/100 mLminj1,
the mean BV was 4.9 T 2.4 mL/100 mL, and the mean MTTwas 8.9 T
3.7 seconds. A pictorial example is given in Figure 1. Both CTP pa-
rameters and MVD were significantly higher in patients with high-
grade tumors compared with those with intermediate-grade tumors
(P G 0.01 for BF, BV, and MVD). When broken down further into sGS
and sGG groups, only the differences in BV and MVD remained at
FIGURE 1. Patient with prostate cancer and GS 7 (3 + 4). Color-coded maps of perfusion parameters BF (28.5 mL/100 mL minj1)
(A), BV (4.1 mL/100 mL) (B), and MTT (8.1 seconds) (C) are shown.
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a statistically significant level among these groups, with overall
higher values in higher sGS and sGG tumors. Detailed results are
provided in Table 2.
Moderate correlations were found between BF and sGS (0.38;
P G 0.01) and between BV and sGS (0.43; P G 0.01). Only weak to
moderate correlations of borderline significance were found between
BV and bGS as well as bGG. No correlation was observed between
perfusion parameters and MVD as well as T stage (Table 3).
The regression analysis showed linear relationships of BV to
sGS (correlation coefficient of determination [r2] = 0.37; Fig. 2A)
as well as to sGG (r2 = 0.25; Fig. 2A). No valuable linear relations
were found between perfusion parameters and T stage as well as
MVD (Table 4).
The ROC analysis revealed that BV (area under the curve
[AUC], 0.86; P = 0.001) was superior to BF (AUC, 0.79; P = 0.003)
as well as to bGS (AUC, 0.75; P = 0.02) in discriminating high-grade
tumors from intermediate-grade tumors (Fig. 3).
DISCUSSION
Oncologic perfusion imaging relies on functional and structural
interference in tissue induced by a tumor.36 So far, CTP has been used in
a variety of neoplasms, including head and neck cancer, lung cancer,
colorectal cancer, and hepatocellular carcinoma.17Y19,37Y39 However,
there are only a few studies available investigating CTP in prostate
cancer, and in part, they show contradictory results concerning its fea-
sibility and usefulness.22,23,26Y28
En Bloc Approach
There are several factors that challenge CTP in this glandular
organ. The lack of contrast resolution makes it impossible to visually
localize cancer on nonenhanced CT.13,23 This challenged the centering
of the perfusion volume in older studies at times when only z-axis
coverage of less than 4 cm was available.22,23,26,27 But even with
today’s 256-slice scanners that allow for a much larger z-axis (up to
28 cm), it is still almost impossible to localize prostate cancer on
contrast-enhanced CT images in the absence of extracapsular spread.
This limits a retrospective approach to CTP, although thewhole prostate
can now be covered easily. Furthermore, neighboring pelvic bones
cause streak artifacts and beam-hardening artifacts on CT images,
TABLE 2. CT-Perfusion Parameters and Microvessel Density Stratified by Tumor Aggressiveness
Perfusion Parameters
n
BF BV
Mean T SD,
mL/100 mL minj1 P
Mean T SD,
mL/100 mL P
All patients 46 39.1 T 13.4 4.9 T 2.4
Intermediate-grade
tumor patients
(sGS 7)
36 36.4 T 12.3 G0.01 4.2 T 1.6 G0.001
High-grade
tumor patients
(sGS 97)
9 50.5 T 12.8 7.6 T 3.1
sGS
6 7 8 0.06 6 7 8 G0.01
6 1 35.4 N/A 0.93 0.13 5.2 N/A 0.33 0.32
7 36 36.4 T 12.3 0.93 N/A 0.01 4.2 T 1.6 0.33 N/A G0.01
8 6 50.3 T 8.7 0.13 0.01 N/A 6.5 T 1.3 0.32 G0.01 N/A
9 3 51.0 T 21.5 0.66 0.21 0.61 9.9 T 4.9 0.66 0.03 0.30
sGG
6 (3 + 3) 7 (3 + 4) 7 (4 + 3) 8 (4 + 4) 8 (5 + 3) 0.19 6 (3 + 3) 7 (3 + 4) 7 (4 + 3) 8 (4 + 4) 8 (5 + 3) 0.01
6 (3 + 3) 1 35.4 N/A 0.87 1.00 0.14 0.32 5.2 N/A 0.41 0.26 0.14 0.32
7 (3 + 4) 20 37.1 T 10.8 0.87 N/A 0.70 0.04 0.19 4.5 T 1.4 0.41 N/A 0.18 G0.01 0.87
7 (4 + 3) 16 35.4 T 14.3 1.00 0.70 N/A 0.06 0.15 3.8 T 1.7 0.26 0.18 N/A G0.01 0.84
8 (4 + 4) 5 49.2 T 9.2 0.14 0.04 0.06 N/A 0.38 6.9 T 0.9 0.14 G0.01 G0.01 N/A 0.14
8 (5 + 3) 1 55.9 0.32 0.19 0.15 0.38 N/A 4.3 0.32 0.87 0.84 0.14 N/A
9 (4 + 5) 3 51.0 T 21.5 0.66 0.24 0.22 0.66 0.66 9.9 T 4.9 0.66 0.05 0.03 0.46 0.18
BF indicates blood flow; BV, blood volume; MTT, mean transit time; N/A, not applicable; sGS, Gleason score of surgical specimens; sGG, combined Gleason
grade of surgical specimens.
TABLE 3. Spearman Correlation Coefficients (r) of CT-Perfusion
Parameters and Gleason Parameters, T Stage, and MVD
BF BV MTT
r P r P r P
bGS 0.27 0.07 0.30 0.04 0.13 0.39
bGG 0.26 0.08 0.29 0.05 0.15 0.32
sGS 0.38 G0.01 0.43 G0.01 0.30 0.04
sGG 0.27 0.07 0.22 0.14 0.22 0.15
T stage j0.01 0.96 0.13 0.40 0.18 0.22
MVD* 0.26 0.16 0.18 0.33 0.16 0.38
BF indicates blood flow; BV, blood volume; MTT, mean transit time; bGS,
Gleason score of biopsy specimens; bGG, combined Gleason grade of biopsy
specimens; sGS, Gleason score of surgical specimens; sGG, combined Gleason
grade of surgical specimens; MVD, microvessel density.
*Data available from 32 subjects only (25 intermediate-grade tumor pa-
tients, 7 high-grade tumor patients).
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which might degrade perfusion data. Thus, the standard approach in
CTP imaging, selectively analyzing areas within the organ that corre-
spond to tumor, is compromised. Our rationale in the present study
was therefore to use an en bloc approach.
Comparison With Histopathology
Our study represents the first systematic evaluation of en bloc
DCE CT in patients with prostate cancer and 1 of the first studies to
address the relationship between CTP parameters and histopathological
grading. A direct comparison of perfusion data with whole-mount
histopathological specimens would be a desirable way to clarify if
CTP imaging is valuable in prostate cancer. However, because of the
small size of the prostate and of the limited spatial resolution of
parametric maps derived from CTP, this comparison is challenging.23
Furthermore, prostate cancer is multifocal in most patients, with dif-
ferent sites often exhibiting different histological grades. Osimani and
coworkers23 found a correlation between BV and MVD. Their BV in
fields with prostate cancer was 8.45 T 2.75 mL/100 mL; however,
there was considerable overlap in BV values of fields with prostate
cancer, benign hyperplasia, and healthy tissue.23 In our study, we
found no significant correlation of perfusion parameters with MVD.
This might be due to our en bloc approach, which might blur such a
relationship between tumor-derived MVD and whole-prostate-derived
perfusion parameters. Other explanations might be the rather small
Microvessel Density, 1/mm2
MTT
Mean T SD, s P n P
8.9 T 3.7 32 144.3 T 55.6
8.5 T 3.8 0.03 25 127.6 T 42.4 G0.01
10.7 T 3.2 7 204.1 T 58.5
6 7 8 0.06 6 7 8 0.02
9.5 N/A 0.35 0.62 0 N/A N/A N/A N/A
8.5 T 3.8 0.35 N/A 0.25 25 127.6 T 42.4 N/A N/A 0.03
9.3 T 2.2 0.62 0.25 N/A 4 213.5 T 70.1 N/A 0.03 N/A
13.6 T 3.1 0.18 0.02 0.20 3 191.6 T 49.8 N/A 0.05 0.72
6 (3 + 3) 7 (3 + 4) 7 (4 + 3) 8 (4 + 4) 8 (5 + 3) 0.08 6 (3 + 3) 7 (3 + 4) 7 (4 + 3) 8 (4 + 4) 8 (5 + 3) G0.01
9.5 N/A 0.51 0.22 0.38 0.32 0 N/A N/A N/A N/A N/A N/A
9.0 T 4.7 0.51 N/A 0.89 0.15 0.32 13 107.9 T 45.7 N/A N/A 0.02 0.01 N/A
7.8 T 2.0 0.22 0.89 N/A 0.07 0.31 12 148.9 T 26.5 N/A 0.02 N/A 0.12 N/A
9.9 T 1.8 0.38 0.15 0.07 N/A 0.14 4 213.5 T 70.1 N/A 0.01 0.12 N/A N/A
6.2 0.32 0.32 0.31 0.14 N/A 0 N/A N/A N/A N/A N/A N/A
13.6 T 3.1 0.18 0.05 0.01 0.03 0.18 3 191.6 T 49.8 N/A 0.04 0.11 0.72 N/A
FIGURE 2. Linear regression analysis of BV and sGS (r 2 = 0.37) (A) and BV and sGG (r 2 = 0.25) (B). r 2 indicates regression
coefficient of determination.
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number of subjects with MVD data available or the use of CD34
staining for MVD analysis, which might be inferior to CD31 staining.40
Besides, it was also shown in recent magnetic resonance (MR) studies
that BV does not consistently correlate with histological parameters.40,41
However, we found a moderate correlation of the perfusion parameters
BF and BV with the GS, notably a clinically more relevant parameter
than MVD.
We could also demonstrate a linearly directed relationship be-
tween the GS and BF as well as BV. Osimani and coworkers did not
provide data on the association of DCE CT parameters and histological
tumor grade because they included only patients with a GS of 7. In the
present study, we found higher BF and BV in patients with high-grade
tumors (GS 97) compared with patients with intermediate-grade tu-
mors (GS 7). The higher the GS (sGS) and the GG (sGG), the higher
BV was by trend. This suggests that the correlation of BV and MVD
that was proposed by Osimani et al might be reflected by a higher BV
in high-grade tumors, which survives through a rather coarse approach
such as en bloc DCE analysis. Thus, we suppose that the decreasing
tumor differentiation from low to high GS might be reflected by a
reciprocal increase in perfusion parameters BVand BF, possibly because
of increased tumor vascularityVat least concerning intermediate- and
high-grade tumorsVwhereas our data do not allow assumption of such
a relationship for low-grade tumors. With DCE MR studies, it was
shown that quantitative (transfer constant) and semiquantitative
(wash-in gradient, wash-out gradient) parameters of prostate cancer
tissue are correlated with the GS.25,42
Discrimination of Tumor Grades
Using an ROC analysis, we were also able to show that BV de-
rived from the en bloc perfusion method was a better diagnostic test
than was the biopsy GS for the differentiation of intermediate-grade
from high-grade tumors. Thus, the tumor aggressiveness might be
predicted more accurately by BV than by the GS of biopsy specimens.
With TRUS-guided biopsy serving as standard of reference, Chen
et al25 showed that the wash-out gradient derived by DCE MR is also
able to differentiate between aggressive and less aggressive histological
subtypes of prostate cancer. Vos and coworkers42 demonstrated that low-
grade peripheral zone tumors can be discriminated from intermediate-
and high-grade peripheral zone tumors by transfer constant, rate constant
(AUC, 0.72), wash-in gradient, and wash-out gradient from DCE MR,
with prostatectomy serving as standard of reference. It is known that
the GSs of biopsy and prostatectomy specimens might differ consid-
erably, which is caused by unrepresentative sampling, and not to a real
change. Upgrading of the GS, as in the present study, has been observed
in several previous studies.2Y4 However, we believe that the perfor-
mance of TRUS-guided biopsy in our study cohort was still comparably
good, given the linear relationship of sGS and bGG (r2 = 0.29).
Tumor Stage
Being reflected by a higher GS, aggressive tumors are asso-
ciated with a more advanced tumor stage than less aggressive tumors
are.31,43 In the present study, we found no significant correlation
between perfusion parameters and tumor stage. This is probably re-
lated to the large portion of subjects (74%) in the same tumor stage
(pT2c) and is supported by the fact that we found no significant
correlation between T stage and sGS (r = 0.22, P = 0.14). Analo-
gously, Ives and coworkers26 found a significant correlation of DCE
CT parameters and tumor size only in 2 of 10 subjects (20%) with
high-grade tumors.
Clinical Implementation and Radiation Burden
Because a perfusion procedure is readily implemented into a
contrast-enhanced CT scan, CTP could potentially serve as an add-on
to a pelvic CT scan for prostate cancer staging, besides being less
time-consuming than functional MRI. We however acknowledge that
CTP suffers from several drawbacks, such as lack of simultaneous
high-quality anatomical information within prostate tissue and com-
parably high radiation burden, and hence will possibly be relevant
only for a small population, such as patients with contraindications
to MRI or institutions without an MR scanner. However, for these
restricted populations, it might be of value to know whether CTP per-
forms better than TRUS-guided biopsy.
Radiation exposure to patients is of growing importance, and
MR perfusion, being the competing standard, has a distinct advant-
age over CTP here. The radiation dose of our protocol is within the
range of usual body CTP protocols in oncology.44,45 Within the direct
x-ray beam in prostatic CTP, the organ that is most vulnerable to radi-
ation is the prostate itself, and no other sensitive organs are contained
within the x-ray volume besides the bone marrow. The prostate is
usually sought to undergo definitive therapy, either by surgery or by ra-
diation therapy, and unlike in other oncological CTP applications, such
as colorectal cancer or lung cancer, no functioning prostate paren-
chyma is left after therapy. Considering the proximity of the x-ray
volume to the gonads, there is, however, the issue of scatter radiation,
which might not play a major role in prostate cancer patients, who are
usually of an advanced age at diagnosis (median of 67 years in our cohort).
Limitations
Several limitations have to be accounted for in our study. One
major limitation is of course the radiation dose delivered to the
FIGURE 3. ROC curves of the discriminating performance
between intermediate- and high-grade cancers. BV (green line;
AUC, 0.86; CI, 0.73Y0.99; P = 0.001) was superior to BF
(blue line) (AUC, 0.79; CI, 0.62Y0.96; P = 0.003) and bGS
(beige line) (AUC, 0.75; CI, 0.57Y0.93; P = 0.02). CI indicates
confidence interval.
TABLE 4. Linear Regression Coefficients of Determination (r 2) of
Postsurgical Histopathological Results
Endogenous
Variables
Exogenous Variables
BF BV MTT bGS bGG
sGS 0.15 0.37 0.09 0.23 0.29
sGG 0.12 0.25 0.04 0.13 0.14
T stage 0.01 0.01 0.01 0.13 0.14
MVD* 0.07 0.10 0.01 0.05 0.06
BF indicates blood flow; BV, blood volume; MTT, mean transit time; bGS,
Gleason score of biopsy specimens; bGG, combined Gleason grade of biopsy
specimens; sGS, Gleason score of surgical specimens; sGG, combined Gleason
grade of surgical specimens; MVD, microvessel density.
*Data available from 32 subjects only.
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patient, with the effective dose being comparatively higher than that of
a standard pelvic CT. Another limitation is the time interval between
CTP examination and prostatectomy (median of 63 days). Tumors
might change during that period. However, prostate cancer usually is
of a slow-growing nature, and thereby, a degradation of results is un-
likely. Despite the initial inclusion of 98 patients, there were MVD
data available in only 32 subjects, which might have contributed to the
lack of correlation with CTP parameters. Another major limitation
is that there was only a single low-grade tumor in our cohort, which
limits our results to intermediate- and high-grade tumors. This is cer-
tainly a selection bias because low-grade tumors are usually not treated
by prostatectomy. This limitation is particularly important because
low-grade tumors might undergo active surveillance, and all other
tumors are treated in some way in most patients. Blood flow, BV, and
MTT provide information only on perfusion and not on permeability
of vessels and presumed contrast leakage in tumoral tissue. We also
did not account for benign prostatic hyperplasia, necrosis, fibrosis,
chronic prostatitis, and other factors that might have an influence on
the perfusion parameters.
CONCLUSION
This is the first study to demonstrate the relationship between
DCE CT parameters derived from an en bloc approach and histo-
pathological grading in prostate cancer. It may be considered a first
step to clarify if DCE CT parameters can give pertinent information
related to histological benchmarks such as the GS. We found that BV
is different among different tumor grades and predicts high-grade tu-
mors better than the GS of biopsy specimens does. Further studies
with a more specific approach to perfusion imaging and histopa-
thology are needed to define a possible value of DCE CT in prostate
cancer patients.
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